title: Preliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues.
abstract: BACKGROUND
  Triple negative breast cancer (TNBC) and often basal-like cancers are defined as negative for estrogen receptor, progesterone receptor and Her2 gene expression. Over the past few years an incredible amount of data has been generated defining the molecular characteristics of both cancers. The aim of these studies is to better understand the cancers and identify genes and molecular pathways that might be useful as targeted therapies. In an attempt to contribute to the understanding of basal-like/TNBC, we examined the Gene Expression Omnibus (GEO) public datasets in search of genes that might define basal-like/TNBC. The Il32 gene was identified as a candidate.
  
  
  RESULTS
  Analysis of several GEO datasets showed differential expression of IL32 in patient samples previously designated as basal and/or TNBC compared to normal and luminal breast samples. As validation of the GEO results, RNA and protein expression levels were examined using MCF7 and MDA MB231 cell lines and tissue microarrays (TMAs). IL32 gene expression levels were higher in MDA MB231 compared to MCF7. Analysis of TMAs showed 42% of TNBC tissues and 25% of the non-TNBC were positive for IL32, while non-malignant patient samples and all but one hyperplastic tissue sample demonstrated lower levels of IL32 protein expression.
  
  
  CONCLUSIONS
  Data obtained from several publically available GEO datasets showed overexpression of IL32 gene in basal-like/TNBC samples compared to normal and luminal samples. In support of these data, analysis of TMA clinical samples demonstrated a particular pattern of IL32 differential expression. Considered together, these data suggest IL32 is a candidate suitable for further study.
authors.affiliation: The Department of Biology, Texas Southern University, Houston, Texas 77004, USA. playeran@tsu.edu.
authors.forename: Audrey
authors.initials: A
authors.lastname: Player
authors.forename: Tim
authors.initials: T
authors.lastname: Oguamanam
authors.forename: Jennifer
authors.initials: J
authors.lastname: Okanmelu
authors.forename: Kayla
authors.initials: K
authors.lastname: Burrell
authors.forename: Mario
authors.initials: M
authors.lastname: Hollomon
mesh_terms: D045744:Cell Line, Tumor; D030541:Databases, Genetic; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007378:Interleukins / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D046888:Tissue Array Analysis; D064726:Triple Negative Breast Neoplasms / Q000235:genetics*
chemical_list: C496971:IL32 protein, human; D007378:Interleukins; D012333:RNA, Messenger
references.citation: Nucleic Acids Res. 2007 Jul;35(Web Server issue):W71-4
references.pmid: 17485472
references.citation: Curr Opin Allergy Clin Immunol. 2013 Feb;13(1):13-8
references.pmid: 23242112
references.citation: Breast Cancer Res. 2011 Oct 06;13(5):R97
references.pmid: 21978456
references.citation: Bioinformatics. 2007 Aug 15;23(16):2088-95
references.pmid: 17553856
references.citation: Med Oncol. 2013 Jun;30(2):472
references.pmid: 23479179
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5678-85
references.pmid: 16115903
references.citation: Int J Oncol. 2012 Apr;40(4):1171-9
references.pmid: 22134360
references.citation: Immunity. 2005 Jan;22(1):131-42
references.pmid: 15664165
references.citation: Cancer Res. 2013 Jun 1;73(11):3470-80
references.pmid: 23633491
references.citation: Diagn Mol Pathol. 2007 Dec;16(4):189-97
references.pmid: 18043281
references.citation: Clin Cancer Res. 2013 Dec 1;19(23):6380-8
references.pmid: 24298068
references.citation: Stem Cells Dev. 2006 Jun;15(3):315-23
references.pmid: 16846370
references.citation: Oncogene. 2011 Jul 28;30(30):3345-59
references.pmid: 21423208
references.citation: PLoS Med. 2006 Aug;3(8):e277
references.pmid: 16903774
references.citation: Nucleic Acids Res. 1988 Nov 25;16(22):10881-90
references.pmid: 2849754
references.citation: Asian Pac J Allergy Immunol. 2013 Mar;31(1):73-8
references.pmid: 23517397
references.citation: Am J Respir Crit Care Med. 2009 Oct 15;180(8):769-79
references.pmid: 19628777
references.citation: Nucleic Acids Res. 2002 Jan 1;30(1):207-10
references.pmid: 11752295
references.citation: J Allergy Clin Immunol. 2010 Apr;125(4):858-865.e10
references.pmid: 20227751
references.citation: Breast Cancer Res Treat. 2008 May;109(1):123-39
references.pmid: 17578664
references.citation: Egypt J Immunol. 2004;11(2):165-70
references.pmid: 16734129
references.citation: Cytokine. 2010 Feb;49(2):171-6
references.pmid: 19880327
references.citation: J Clin Oncol. 2010 Jan 1;28(1):105-13
references.pmid: 19917869
references.citation: Clin Exp Immunol. 2007 Sep;149(3):480-6
references.pmid: 17590175
references.citation: Allergy. 2012 Jan;67(1):25-32
references.pmid: 21899560
references.citation: Cancer Lett. 2012 May 28;318(2):226-33
references.pmid: 22198481
references.citation: Mol Cell Proteomics. 2005 Dec;4(12):1920-32
references.pmid: 16127175
references.citation: Am J Respir Crit Care Med. 2008 Nov 1;178(9):894-901
references.pmid: 18703789
references.citation: Eur Cytokine Netw. 2005 Dec;16(4):289-92
references.pmid: 16464743
references.citation: Int Immunol. 2011 Nov;23(11):679-91
references.pmid: 22033195
references.citation: J Microbiol Biotechnol. 2008 Sep;18(9):1606-12
references.pmid: 18852519
references.citation: J Clin Invest. 2013 Jul;123(7):2873-92
references.pmid: 23778140
references.citation: Breast Cancer Res. 2009;11(2):R15
references.pmid: 19272155
references.citation: Nucleic Acids Res. 2010 Jan;38(Database issue):D613-9
references.pmid: 19906737
references.citation: Cell Oncol (Dordr). 2013 Dec;36(6):493-503
references.pmid: 24114327
references.citation: J Immunol. 1992 Jan 15;148(2):597-603
references.pmid: 1729377
references.citation: Int J Cancer. 2009 Apr 15;124(8):1756-66
references.pmid: 19115200
references.citation: J Clin Invest. 2011 Jul;121(7):2750-67
references.pmid: 21633166
references.citation: Oncologist. 2013;18(2):123-33
references.pmid: 23404817